Daniil Stroyakovskiy
City Clinical Hospital(RU)Moscow City Oncology Hospital №62(RU)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC(2018)3,693 cited
- → Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma(2014)2,015 cited
- → Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma(2014)1,843 cited
- → Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial(2015)1,372 cited
- → Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma(2019)1,339 cited
- → Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial(2016)994 cited
- → Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial(2019)924 cited
- → Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial(2023)809 cited
- → Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study(2017)647 cited
- → Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial(2020)638 cited